M&A Deal Summary

SOBI Acquires CTI BioPharma

On May 10, 2023, SOBI acquired life science company CTI BioPharma for 1.7B USD

Acquisition Highlights
  • This is SOBI’s 3rd transaction in the Life Science sector.
  • This is SOBI’s largest (disclosed) transaction.
  • This is SOBI’s 2nd transaction in the United States.
  • This is SOBI’s 1st transaction in Washington.

M&A Deal Summary
Date 2023-05-10
Target CTI BioPharma
Sector Life Science
Buyer(s) SOBI
Deal Type Add-on Acquisition
Deal Value 1.7B USD

Target

CTI BioPharma

Seattle, Washington, United States
website
CTI is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI BioPharma was founded in 1991 and is based in Seattle, Washington.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SOBI

Stockholm 

, Sweden

website

Category Company
Sector Life Science
Employees1,537
Revenue 15.3B SEK (2020)
DESCRIPTION

SOBI a integrated biopharmaceutical company with international market presence, developing and commercializing pharmaceuticals for patients with rare diseases.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 4 of 4
State (Washington) 1 of 1
Country (United States) 2 of 2
Year (2023) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-30 Dova Pharmaceuticals

Durham, North Carolina, United States

Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina.

Buy $915M
Mergr

Product

Company

Legal